Laurus Labs Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹1,778Cr
- +25.7% YoY
- +7.6% QoQ
- Net profit
- ₹252Cr
- +171% YoY
- +29.9% QoQ
- Margin
- 27%
- +7 pp YoY
- +3 pp QoQ
Guidance rank: #58 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Laurus Labs Ltd Q3 FY26 key numbers
- Revenue
- ARV segment revenues expected to remain in the range of Rs. 2,500 to 3,000 crores.
As stated in Laurus Labs Ltd's Q3 FY26 earnings call transcript · published 8 Aug 2026. Reported figures, not investment advice.
Revenue & Sales Performance
- API and formulation segments expected to grow significantly in FY’28, with some growth in FY’27 due to new capacities and validations. (Page 21)
- ARV segment revenues expected to remain in the range of Rs. 2,500 to 3,000 crores. (Page 21)
- Generic API business growth viewed as very sustainable; FDF business growth also expected to be sustainable due to new capacities and volume gains. (Pages 15, 21)
- CDMO business reported 50% growth in 9 months FY’26; expects continued healthy growth in Q4 FY’26 and qualitative growth in FY’27 driven mainly by commercial supplies. (Pages 12, 14)
- Non-ARV formulations expected to sustain growth supported by additional capacities for CMO partners in Europe and new launches in North America. (Page 19)
2 more points from Laurus Labs Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Laurus Labs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- New greenfield CAPEX of 500 acres in Atchutapuram: land allotment expected in Q4 FY'26; CAPEX to start in second half of FY'27; qualification and validation expected two years later (around FY'29).
- Joint venture with Krka Pharma: Phase-1 includes 3 billion solid oral tablet capacity and 100 million potent tablet capacity; Phase-1 expected completion by mid-2027; Phase-2 to add 5 billion solid oral tablet capacity.
- Peptide CDMO commercial manufacturing facility: qualification expected during calendar year 2026; integrated capacity being created including amino acids and peptide processing.
- ADC (antibody drug conjugates) GMP facility: $25 million allocated for construction; no meaningful revenue expected in next two years; investments ongoing in both CAPEX and OPEX.
2 more points from Laurus Labs Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Laurus Labs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- It's mentioned that the CDMO business has strong recurring business from existing long-term customer relationships and a healthy pipeline with a well-balanced mix of big pharma, mid-, and small-sized biotechs.
- The company supplies multiple commercial molecules and is investing in capacity expansion, including peptides and advanced technologies.
- For human health CDMO, several programs with partners are ongoing with commercial supplies.
2 more points from Laurus Labs Ltd's call on order book
Create a free account to keep reading this call
Laurus Labs Ltd — Quarterly revenue & net profit
Laurus Labs Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 1,778 | 1,415 | +25.7% | 1,653 | +7.6% |
| Operating profit (EBITDA) | 480 | 285 | +68.4% | 403 | +19.1% |
| Operating margin | 27% | 20% | +7 pp | 24% | +3 pp |
| Profit before tax | 327 | 131 | +149.6% | 270 | +21.1% |
| Net profit (PAT) | 252 | 93 | +171% | 194 | +29.9% |
| EPS (₹) | 4.66 | 1.71 | +172.5% | 3.61 | +29.1% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.2K Cr, net profit ₹436 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Laurus Labs's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Laurus Labs Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What is Laurus Labs Ltd share price analysis?
Laurus Labs Ltd currently shows a neutral. The stock trades at a P/E of 88.3 with a market cap of ₹96,570 Cr. Investors should review the full earnings analysis for detailed insights.
Is Laurus Labs Ltd planning capital expenditure?
New greenfield CAPEX of 500 acres in Atchutapuram: land allotment expected in Q4 FY'26; CAPEX to start in second half of FY'27; qualification and validation expected two years later (around FY'29).
Keep Laurus Labs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
